Cardiorenal risk reduction guidance in diabetes: can we reach consensus?

Since the early 2000s, the number of diabetes drugs has more than doubled and over 20 cardiovascular or renal outcome trials have been completed. The new evidence has accrued at such a rapid rate that many health-care professionals are struggling to keep up. Guideline and consensus committees are tasked with summarising the evidence in a manner that is balanced, easily digestible, and...